Si Yameng

Si Yameng


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2020 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
SYSi Yameng
Si Yameng
JHJiadong Huang
Jiadong Huang
XLXiang Li
Xiang Li
YFYu Fu
Yu Fu
RXRongyao Xu
Rongyao Xu
HJHongbing Jiang
Hongbing Jiang
Background: Venous malformations (VMs), most of which associated with activating mutations in the endothelial cells (ECs) tyrosine kinase receptor TIE2, are characterized by dilated and immature veins with scarce smooth muscle cells (SMCs) coverage. However, the underlying mechanism of interaction between ECs and SMCs responsible for VMs has not been fully understood.Methods: Here, we screened 5 patients with TIE2-L914F mutation who were diagnosed with VMs by SNP sequencing, and we compared the expression of platelet-derived growth factor beta (PDGFB) and α-SMA in TIE2 mutant veins and normal veins by immunohistochemistry. In vitro, we generated TIE2-L914F-expressing human umbilical vein endothelial cells (HUVECs) and performed BrdU, CCK-8, transwell and tube formation experiments on none-transfected and transfected ECs. Then we investigated the effects of rapamycin (RAPA) on cellular characteristics. Next we established a co-culture system and investigated the role of AKT/FOXO1/PDGFB in regulating cross-talking of mutant ECs and SMCs.Results: VMs with TIE2-L914F mutation showed lower expression of PDGFB and α-SMA than normal veins. TIE2 mutant ECs revealed enhanced cell viability and motility, and decreased tube formation, whereas these phenotypes could be reversed by rapamycin. Mechanically, RAPA ameliorated the physiological function of mutant ECs by inhibiting AKT-mTOR pathway, but also facilitated the nuclear location of FOXO1 and the expression of PDGFB in mutant ECs, and then improved paracrine interactions between ECs and SMCs. Moreover, TIE2 mutant ECs strongly accelerated the transition of SMCs from contractile phenotype to synthetic phenotype, whereas RAPA could prevent the phenotype transition of SMCs.Conclusions: Our data demonstrate a previously unknown mechanistic linkage of AKT-mTOR/FOXO1 pathway between mutant ECs and SMCs in modulating venous dysmorphogenesis, and AKT/FOXO1 axis might be a potential therapeutic target for the recovery of TIE2-mutation causing VMs.Graphical

8 August 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
WHWeijian HU
Weijian HU
SYSi Yameng
Si Yameng
XXXin Xie
Xin Xie
JXJiabin Xu
Jiabin Xu
Icariin (ICA) is a bioactive flavonoid compound extracted from Epimedium plants. In recent years, it has attracted significant research interest in the field of bone tissue repair due to its pharmacological effects via multiple targets and pathways. Studies have shown that ICA promotes the osteogenic differentiation of mesenchymal stem cells (MSCs) and enhances bone matrix formation by regulating signaling pathways such as Akt and Wnt/β-catenin. It concurrently inhibits osteoclast activity to maintain the balance of bone remodeling, thereby simultaneously stimulating new bone regeneration and suppressing bone resorption. At the same time, ICA exerts potent anti-inflammatory and antioxidant effects and promotes angiogenesis, improving the local microenvironment of bone injury and significantly facilitating the regeneration of bone and cartilage tissues. Additionally, ICA exhibits notable protective effects in multiple organ systems including the cardiovascular, hepatic, renal, and nervous systems. Specifically, ICA reduces cardiomyocyte apoptosis and fibrosis to preserve cardiac function, improves hepatic metabolic function and alleviates oxidative stress, attenuates renal inflammation and fibrosis, and—through neuroprotective actions—reduces neuroinflammation and promotes neuronal survival. These multi-organ effects help optimize the systemic environment for bone healing. However, ICA faces significant pharmacokinetic challenges. It has low oral bioavailability (due to poor absorption and extensive first-pass metabolism) as well as a short half-life. Consequently, maintaining effective drug concentrations in vivo is difficult, which limits its therapeutic efficacy and impedes clinical translation. To fully realize its regenerative potential, advanced drug delivery strategies (e.g., nanocarrier-based delivery systems) are being explored to enhance ICA’s bioavailability and prolong its duration of action. Overall, ICA’s multi-modal actions on bone cells, the immune microenvironment, and systemic factors make it a promising multi-target agent for bone regeneration. Addressing its pharmacokinetic limitations through optimized delivery and conducting further clinical studies will be crucial to realize its full therapeutic potential. This review provides a comprehensive overview of recent advances and challenges in translating ICA’s benefits into orthopedic therapy.

5 September 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
WHWeijian HU
Weijian HU
SYSi Yameng
Si Yameng
XWXinru Wen
Xinru Wen
DLDuan Lin
Duan Lin
YZYU ZIHAO
YU ZIHAO
JXJiabin Xu
Jiabin Xu
Tanshinone IIA (T-IIA), a fat-soluble diterpene quinone extracted from Salvia miltiorrhiza, is widely recognized for its multiple pharmacological properties, including anti-inflammatory, antioxidant, anti-fibrotic, and anti-tumor effects. Recent studies have highlighted its great potential in treating bone metabolic disorders, especially osteoporosis and bone damage repair. Bone health depends on the dynamic balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Disruption of this balance can lead to diseases such as osteoporosis, which is often diagnosed after a fracture, seriously affecting the quality of life and increasing the medical burden. Early identification of high-risk groups and appropriate treatment are essential for preventing fracture recurrence. Studies have shown that T-IIA can promote osteoblast differentiation and inhibit osteoclast activity, targeting key signaling pathways such as NF-κB, PI3K/Akt, and Wnt/β-catenin, all of which are closely related to bone metabolism. T-IIA has a dual role in regulating bone formation and bone resorption, making it a potential drug for the treatment of osteoporosis. In addition, T-IIA has neuroprotective, hepatic, renal, cardiac, and cerebral effects, which enhance its therapeutic effect. Despite the remarkable efficacy of T-IIA, its clinical application is limited due to poor solubility and low bioavailability. Recent advances in drug delivery systems, such as liposome formulations and nanocarriers, have improved their pharmacokinetics, increased absorption rate, and bioavailability. Combination therapy with growth factors or stem cells can further enhance its efficacy. Future studies should focus on optimizing the delivery system of T-IIA and exploring its combined application with other therapeutic strategies to expand its clinical application range.

16 October 2025 in Journal of Cranio-Maxillofacial Surgery
Verified
Journal Article
Open access
ZSZhongjie Shi
Zhongjie Shi
TLTianyi Li
Tianyi Li
JKJianguo Ke
Jianguo Ke
JLJia Li
Jia Li
XGXin Gao
Xin Gao
ZWZhanxiang Wang
Zhanxiang Wang
To develop a novel mixed reality (MR)-based portable navigation system for oral and maxillofacial surgery (OMFS) and to evaluate its feasibility and spatial accuracy in clinical applications. The MR-based system was developed using Microsoft HoloLens 2, leveraging its built-in near-infrared cameras for reflective marker tracking. A customized software module, developed on the 3D Slicer platform, enabled automatic registration and real-time 3D anatomical visualization through a spatial pose filtering algorithm. A non-invasive patient-specific dental bracket was fabricated using silicone rubber for fixation and registration. A prospective clinical trial involving 24 patients was conducted. Navigation performance was quantitatively assessed by comparing preoperative and intraoperative registration errors, and qualitatively evaluated based on lesion overlap observed through the MR headset. The proposed MR system successfully achieved real-time 3D visualization and immersive intraoperative navigation without the use of external tracking devices. The mean preoperative localization error was 1.64 ± 0.78 mm, and the intraoperative error was 1.65 ± 1.00 mm (p = 0.44), indicating no significant difference. Among the 24 cases, 83.3 % demonstrated high virtual-to-actual concordance, while 16.7 % showed moderate concordance. The average data processing time was 8.38 ± 0.83 min, with improved efficiency observed over repeated trials. The MR-based navigation system demonstrated good feasibility, accuracy, and usability for OMFS procedures. Its low cost, non-invasive design, and flexibility make it a promising intelligent surgical guidance tool for routine clinical practice, particularly in primary healthcare settings.